Patents by Inventor John Desmond Wade

John Desmond Wade has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10081662
    Abstract: Provided herein are biologically active single chain relaxin peptides. In particular the present invention relates to single chain relaxin peptides comprising a B chain derived from relaxin-2, the peptide being truncated by one or more amino acid residues at the N-terminus with respect to the sequence of the B chain of native relaxin-2. Typically the single chain relaxin peptides selectively bind to the RXFP1 receptor.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: September 25, 2018
    Assignee: THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH
    Inventors: Ross Alexander David Bathgate, Mohammed Akhter Hossain, John Desmond Wade
  • Publication number: 20170037106
    Abstract: Provided herein are biologically active single chain relaxin peptides. In particular the present invention relates to single chain relaxin peptides comprising a B chain derived from relaxin-2, the peptide being truncated by one or more amino acid residues at the N-terminus with respect to the sequence of the B chain of native relaxin-2. Typically the single chain relaxin peptides selectively bind to the RXFP1 receptor.
    Type: Application
    Filed: April 17, 2015
    Publication date: February 9, 2017
    Inventors: Ross Alexander David BATHGATE, Mohammed Akhter HOSSAIN, John Desmond WADE
  • Patent number: 9359422
    Abstract: The present invention relates to biologically active single chain relaxin polypeptides comprising a relaxin B chain derived from relaxin-3, the polypeptides being truncated by one or more amino acids at the C-terminus of the relaxin-3 B chain. Typically the single chain relaxin polypeptides are antagonists of the RXFP3 receptor, and in some embodiments are selective antagonists of the RXFP3 receptor.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: June 7, 2016
    Assignees: The University of Queensland, Howard Florey Institute of Experimental Physiology and Medicine
    Inventors: Karl Johan Rosengren, Linda Maria Haugaard-Kedstrom, Ross Alexander David Bathgate, Mohammed Akhter Hossain, John Desmond Wade, Andrew Lawrence Gundlach, Andrew J. Lawrence
  • Patent number: 9056922
    Abstract: Provided herein are modified relaxin polypeptides wherein the B chain comprises the core amino acid sequence CGR-XXX-R-XX-I/V-XX-CG (SEQ ID NO:1), where X is any amino acid. Also provided are modified relaxin polypeptides comprising at least an A and a B chain, wherein the A and B chains are derived from different naturally occurring relaxins and wherein the B chain comprises the core amino acid sequence CGR-XXX-R-XX-I/V-XX-CG (SEQ ID NO:1), where X is any amino acid.
    Type: Grant
    Filed: October 30, 2008
    Date of Patent: June 16, 2015
    Assignee: HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE
    Inventors: Ross Alexander David Bathgate, Mohammed Akhter Hossain, Chrishan Surendran Samuel, John Desmond Wade, Geoffrey W Tregear
  • Patent number: 8841254
    Abstract: Human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues having a modified A chain and/or a modified B chain are described. Also described are nucleic acid sequences encoded human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues. Also described are methods for the treatment of conditions responsive to administration of H3 relaxin or analogues thereof.
    Type: Grant
    Filed: August 21, 2007
    Date of Patent: September 23, 2014
    Assignee: Howard Florey Institute of Experimental Physiology and Medicine
    Inventors: Geoffrey Tregear, Ross Alexander David Bathgate, Chrishan Surendran Samuel, Tanya Christine Burazin, Andrew Lawrence Gundlach, John Desmond Wade
  • Publication number: 20140038895
    Abstract: The present invention relates to biologically active single chain relaxin polypeptides comprising a relaxin B chain derived from relaxin-3, the polypeptides being truncated by one or more amino acids at the C-terminus of the relaxin-3 B chain. Typically the single chain relaxin polypeptides are antagonists of the RXFP3 receptor, and in some embodiments are selective antagonists of the RXFP3 receptor.
    Type: Application
    Filed: September 8, 2011
    Publication date: February 6, 2014
    Applicants: The University of Queensland, Howard Florey Institute of Experimental Physiology and Medicine
    Inventors: Karl Johan Rosengren, Linda Maria Haugaard-Kedstrom, Ross Alexander David Bathgate, Mohammed Akhter Hossain, John Desmond Wade, Andrew Lawrence Gundlach, Andrew J. Lawrence
  • Publication number: 20140024592
    Abstract: The present invention relates to biologically active relaxin polypeptides comprising a relaxin A chain and a B chain derived from a relaxin superfamily member, wherein the A chain comprises no intra-chain disulphide bonds. In particular embodiments the modified polypeptides comprise relaxin-3 derived A and B chains, and truncations of the A and/or B chains from the N-termini and/or C-termini. In particular embodiments the polypeptides of the invention are selective agonists or antagonists of the RXFP3 receptor.
    Type: Application
    Filed: September 8, 2011
    Publication date: January 23, 2014
    Applicant: Howard Florey Institute of Experimental Physiology and Medicine
    Inventors: Fazel Shabenpoor, Mohammed Akhter Hossain, Ross Alexander David Bathgate, John Desmond Wade, Andrew Lawrence Gundlach
  • Publication number: 20110092418
    Abstract: Provided herein are modified relaxin polypeptides wherein the B chain comprises the core amino acid sequence CGR-XXX-R-XX-I/V-XX-CG (SEQ ID NO:1), where X is any amino acid. Also provided are modified relaxin polypeptides comprising at least an A and a B chain, wherein the A and B chains are derived from different naturally occurring relaxins and wherein the B chain comprises the core amino acid sequence CGR-XXX-R-XX-I/V-XX-CG (SEQ ID NO:1), where X is any amino acid.
    Type: Application
    Filed: October 30, 2008
    Publication date: April 21, 2011
    Applicant: FLOREKY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE
    Inventors: Ross Alexander David Bathgate, Mohammed Akhter Hossain, Chrishan Surendran Samuel, John Desmond Wade, Geoffrey W. Tregear
  • Publication number: 20110003750
    Abstract: Human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues having a modified A chain and/or a modified B chain are described. Also described are nucleic acid sequences encoded human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues. Also described are methods for the treatment of conditions responsive to administration of H3 relaxin or analogues thereof.
    Type: Application
    Filed: August 8, 2009
    Publication date: January 6, 2011
    Inventors: Geoffrey William Tregear, Ross Alexander David Bathgate, Chrishan Surendran Samuel, Tanya Christine Burazin, Andrew Lawrence Gundlach, John Desmond Wade
  • Publication number: 20090239805
    Abstract: Human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues having a modified A chain and/or a modified B chain are described. Also described are nucleic acid sequences encoded human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues. Also described are methods for the treatment of conditions responsive to administration of H3 relaxin or analogues thereof.
    Type: Application
    Filed: March 27, 2009
    Publication date: September 24, 2009
    Inventors: Geoffrey TREGEAR, Ross Alexander David BATHGATE, Chrishan Surendran SAMUEL, Tanya Christine Burazin, Andrew Lawrence Gundlach, John Desmond Wade
  • Publication number: 20080176795
    Abstract: Human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues having a modified A chain and/or a modified B chain are described. Also described are nucleic acid sequences encoded human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues. Also described are methods for the treatment of conditions responsive to administration of H3 relaxin or analogues thereof.
    Type: Application
    Filed: August 21, 2007
    Publication date: July 24, 2008
    Inventors: Geoffrey Tregear, Ross Alexander David Bathgate, Chrishan Surendran Samuel, Tanya Christine Burazin, Andrew Lawrence Gundlach, John Desmond Wade